Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$GILD Q1 '25 Earnings Results & Recap
Gilead Sciences reported Q1 '25 non-GAAP diluted EPS of $1.81, exceeding the estimate of $1.78; total product sales of $6.6B were slightly below the estimate of $6.81B. The company expects flat HIV sales in 2025 due to Part D headwinds, but anticipates growth across all three therapeutic focus areas (virology, oncology, inflammation) in future years.2
